North East and North Cumbria
ICS Formulary
 
back
10 Musculoskeletal and joint diseases
10-02-01 Drugs used in neuromuscular disorders

Ataluren Translarna®
Formulary
  • Approved as an option for treating Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene in people 2 years and over who can walk - in line with NICE HST22.
Link  NICE HST22: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene

Red View adult BNF  View SPC online  View childrens BNF
Ravulizumab Ultomiris®
Non Formulary
  • 300mg/30ml and 110mg/11ml concentrate for solution for infusion
  • Not recommended for treating generalised myasthenia gravis in adults in line with NICE
  • Not recommended for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder in adults in line with NICE
Link  NICE TA940: Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)
Link  NICE TA941: Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)

Black View adult BNF  View SPC online  View childrens BNF
Satralizumab Enspryng®
Non Formulary
  • Not recommended for preventing relapses in neuromyelitis optica spectrum disorder in line with NICE
Link  NICE TA960: Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders

Black View adult BNF  View SPC online  View childrens BNF